Trevi Therapeutics Reports Q2 2026 Financial Results

What Happened

• Trevi Therapeutics, Inc. (TRVI) filed a Form 8‑K on August 6, 2026 to announce its financial results for the quarter ended June 30, 2026. The company furnished a press release containing the full announcement as Exhibit 99.1 (the exhibit is furnished, not filed). The 8‑K was signed by David C. Hastings, Chief Financial Officer.

Key Details

• Filing date: August 6, 2026 (Form 8‑K).
• Reporting period: Quarter ended June 30, 2026 (Q2 2026 quarterly results).
• Exhibit: Press release issued August 6, 2026 furnished as Exhibit 99.1; Inline XBRL cover page (Exhibit 104) included.
• Signatory: David C. Hastings, Chief Financial Officer, signed the report.

Why It Matters

• This 8‑K provides Trevi’s latest quarterly results and financial condition information for investors to review; the press release (Exhibit 99.1) will contain the detailed earnings, revenue and operating metrics.
• Because the exhibit is furnished (not filed), the press release is being made public for informational purposes; investors should consult the press release and any subsequent filings (e.g., 10‑Q) for full audited or detailed figures.